SUSAN PARKER: Open Payments
NPI 1376508218 · HENAGAR, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$693 in 40 payments from 16 companies in 2025. Trend: 2023 $963 · 2024 $1,021 · 2025 $693
Food & beverage: $693
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $172 |
| Novo Nordisk Inc | 8 | $153 |
| Corcept Therapeutics | 3 | $71 |
| ABBVIE INC. | 3 | $64 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $22 |
| PFIZER INC. | 1 | $22 |
| Indivior Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
Products named: TRELEGY ELLIPTA, Ozempic, Korlym, SHINGRIX, VRAYLAR, Rybelsus, JARDIANCE, Kerendia.
Industry payments across AL — which companies pay providers there.
